Damon Race: Can Gene Therapy Deliver Durable Expression Over Time?
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared on LinkedIn:
”The first generation of hemophilia A gene therapies changed the field in an important way.
The question is no longer simply whether gene therapy can reduce bleeding.
The question is whether gene therapy can deliver durable expression over time.
Patients remain highly interested in gene therapy, but long-term durability has become central to adoption decisions for both patients and providers.
At GeneVentiv, this understanding shaped the design and program development of GENV-HEM (AAV8.FVa), which leverages native hepatic biology associated with Factor V expression.
Importantly, our vision for the future of hemophilia A gene therapy includes inhibitor patients.
Patient decisions to adopt gene therapy will ultimately be made not just by efficacy, but by durability.”
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 21:47Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention
-
Sep 29, 2026, 22:26A Global Call for Action on Cardiovascular Health on World Heart Day – ISTH